ESMO 2022: shrinking market for Trodelvy, with fierce ADC competition
Pharmaceutical Technology
SEPTEMBER 13, 2022
A global Phase III TROPiCS-02 study evaluated the use of Trodelvy in comparison to physicians’ choice of chemotherapy in 543 HR+/HER2- metastatic breast cancer patients who were previously treated with endocrine therapy, CDK 4/6 inhibitors and at least two lines of chemotherapy. months) versus physicians’ choice chemotherapy (11.2
Let's personalize your content